{
    "clinical_study": {
        "@rank": "38522", 
        "acronym": "EFFECT", 
        "arm_group": {
            "arm_group_label": "Single Arm: Eligard", 
            "arm_group_type": "Other", 
            "description": "Single Arm"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the effect of the study medication (Eligard\u00ae) on\n      cancer markers (in the blood) of prostate cancer."
        }, 
        "brief_title": "A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard\u00ae, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The main objective of the study is to explore the effect of Eligard\u00ae on the following\n      prostate cancer biomarkers:\n\n      Testosterone in serum, Prostate Specific Antigen (PSA) in serum, Prostate Cancer Antigen\n      (PCA3 score) in urine, PSA mRNA in blood/Peripheral Blood Mononuclear Cell (PBMC), PCA3 mRNA\n      in blood/PBMC, Transmembrane protease, serine 2-Ets Related Gene (TMPRSS2-ERG) mRNA in\n      blood/PBMC\n\n      A blood sample for RNA analysis will also be collected and stored for future investigation\n      in patients giving specific informed consent."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Confirmed metastatic prostate cancer for whom androgen deprivation therapy (ADT) is\n             indicated.\n\n          -  Non-castrate level of testosterone (\u2265 8 nmol/L (230 ng/dL)) at screening.\n\n          -  Eastern Cooperative Oncology Group (ECOG) score of 0-2\n\n          -  A life expectancy of at least 12 months.\n\n          -  Is able to tolerate injection of study drug and comply with the study requirements.\n\n        Exclusion Criteria:\n\n          -  History of bilateral orchidectomy.\n\n          -  History of any hormonal treatment/therapy with GnRH agonist, GnRH anti-agonist within\n             6 months of enrolment.\n\n          -  Treatment with anti-androgens, 5-\u03b1 reductase inhibitors, estrogens and/or other any\n             investigational hormone-derivative within 3 months of enrolment or 5-times the\n             half-life, whichever is longer.\n\n          -  Any previous treatment with chemotherapy treatment for prostate cancer prior to the\n             screening visit or within 6 months prior to screening for any other cancer.\n\n          -  Patients previously treated for cancer with hormonal therapy in whom treatment was\n             stopped due to lack of efficacy, progression of the disease or lack of tolerability.\n\n          -  Previous treatments for cancer (including prostate cancer) within 6 months prior to\n             enrolment: immunotherapy, external beam radiotherapy, brachytherapy, thermotherapy,\n             or biological response modifiers (e.g. cytokines).\n\n          -  Known or suspected spinal cord compression or evidence of spinal metastases with risk\n             of spinal compression.\n\n          -  Uni- or bilateral ureteric obstruction.\n\n          -  Requiring concomitant use of anti-androgens during the course of the study.\n\n          -  Previous or concomitant malignancies at other sites except effectively treated\n             non-melanoma skin cancer or an effectively treated malignancy that has been in\n             remission for at least 5 years.\n\n          -  Major surgery within 2 months prior to enrolment.\n\n          -  Total bilirubin > 1.5 times the upper limit of normal (ULN) at screening. This will\n             not apply to subjects with Gilbert's syndrome (persistent or recurrent\n             hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of\n             hemolysis or hepatic pathology), who will be allowed in consultation with the\n             sponsor.\n\n          -  Participation in any clinical study within \u2264 1 month prior to screening.\n\n          -  Not available for follow-up assessments or unable to comply with study requirements.\n\n          -  Known or suspected hypersensitivity to leuprorelin acetate, to other GnRH agonists or\n             to any of the excipients of Eligard.\n\n          -  Male subjects who are intending to donate sperm within 9 months following the\n             injection of Eligard\n\n          -  Male subjects and their female spouses/partners who are of childbearing potential and\n             are NOT using highly effective contraception consisting of two forms of birth control\n             (one of which must be a barrier method) starting at Screening and continuing for 9\n             months from the time of the Eligard injection. Acceptable forms include:\n\n               -  Established use of oral, injected or implanted hormonal methods of\n                  contraception.\n\n               -  Placement of an intrauterine device (IUD) or intrauterine system (IUS).\n\n               -  Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/suppository"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01933022", 
            "org_study_id": "EGD-EC-005", 
            "secondary_id": "2012-000101-69"
        }, 
        "intervention": {
            "arm_group_label": "Single Arm: Eligard", 
            "description": "Subcutaneous Injection", 
            "intervention_name": "Eligard", 
            "intervention_type": "Drug", 
            "other_name": "Leuprorelin acetate"
        }, 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic prostate cancer", 
            "Exploratory", 
            "Biomarkers", 
            "Eligard"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "'s-Hertogenbosch", 
                        "country": "Netherlands", 
                        "zip": "5200 ME"
                    }, 
                    "name": "Site: 31003"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hengelo", 
                        "country": "Netherlands", 
                        "zip": "7555 DL"
                    }, 
                    "name": "Site: 31002"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3435 CM"
                    }, 
                    "name": "Site: 31005"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "6532 SZ"
                    }, 
                    "name": "Site: 31001"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "6525 GA"
                    }, 
                    "name": "Site: 31004"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard\u00ae 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Medical Affairs Europe", 
            "phone": "+44(0)20 3379 8000"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe Ltd.", 
            "last_name": "Clinical Study Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes from baseline of Testosterone levels in serum", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Changes from baseline of PSA level in serum", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Changes from baseline of PCA3 score in urine", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Changes from baseline of Number of PSA mRNA copies in blood/PBMC", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Changes from baseline of Number of PCA3 mRNA copies in blood/PBMC", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Changes from baseline of Number of TMPRSS2-ERG mRNA copies in blood/PBMC", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01933022"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of Adverse Events from screening to the end of study visit (as reported by the investigator based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.3)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}